Phase 2 N=54 Basic Science

New Technologies to Determine Carotid Plaque Vulnerability in Patients With Significant Carotid Plaques

Carotid Artery Plaque

Bottom Line

View on ClinicalTrials.gov: NCT03335033 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Nov 2022

Primary outcome: Primary: Number of Subjects Who Completed All of the Ultrasound Examinations — 17; 37 Participants

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: Contrast-enhanced ultrasound (Combination_product); Shear Wave Elastography (Device); Ultrasound Examination (Device)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Mayo Clinic
Primary completion: Jan 2022

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Subjects Who Completed All of the Ultrasound Examinations	17; 37	—

Summary

The researchers are trying to determine if the characterization of "vulnerable" carotid artery plaques can be accomplished with ultrasound-based methods that look for vessels in the plaque and measure the plaque stiffness.

Eligibility Criteria

Inclusion Criteria

Subject has carotid plaque with > 50% stenosis
Subject is able to understand the study procedure and provide informed consent

Exclusion Criteria

Subject is pregnant or breast feeding
Subject is unable to provide informed consent
Subject has contraindication to the use of the Lumason contrast agent.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03335033). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.